2003
DOI: 10.1016/s0168-3659(03)00120-2
|View full text |Cite
|
Sign up to set email alerts
|

Lipid microparticles as sustained release system for a GnRH antagonist (Antide)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
13
0
2

Year Published

2003
2003
2018
2018

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 45 publications
(15 citation statements)
references
References 22 publications
0
13
0
2
Order By: Relevance
“…The in vitro insulin release was slower (incomplete after 13 days) than thymocartin (5 days). Entrapment of gonadotropin-releasing hormone antagonist in LMs has been reported by Del Curto et al [110]. Following s.c. administration in rats, drug plasma levels were detectable for 30 days.…”
Section: Parenteral Administrationmentioning
confidence: 71%
“…The in vitro insulin release was slower (incomplete after 13 days) than thymocartin (5 days). Entrapment of gonadotropin-releasing hormone antagonist in LMs has been reported by Del Curto et al [110]. Following s.c. administration in rats, drug plasma levels were detectable for 30 days.…”
Section: Parenteral Administrationmentioning
confidence: 71%
“…It is more commonly used to investigate particle morphology. SEM has been used to investigate the shape and surface structure of SLNs with respect to changes that occur when placed in contact with different release media (Cortesi et al 2002;Del Curto et al 2003;Reithmeier et al 2001a, b;Savolainen et al 2002). SEM imaging allows observation of SLNs in the absence of aggregation (Dubes et al 2003).…”
Section: Scanning Electron Microscopymentioning
confidence: 99%
“…20) As daily injections are undesirable for long-term treatment, incorporation of LHRH antagonists in sustained release formulations was of interest for the PC indication, e.g. liposome based implant, 21) lipid microparticles 2) and microparticles. 22) LXT-101 ( Fig.…”
Section: Tmmentioning
confidence: 99%
“…by deamidation, Maillard reaction, oxidation and hydrolysis), instability and low bioavailability, make traditional dosage forms not proper to deliver them. 1) Therefore, modern delivery systems like lipid microparticles, 2) nanospheres, 3) and microspheres 4) are applied to carry them though many problems exist. Microspheres prepared from poly(DL-lactide-co-glycolide) (PLGA) polymers have been studied extensively in the last two decades as sustained release dosage forms.…”
mentioning
confidence: 99%